Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Gyre Therapeutics (GYRE) Other Non Operating Income (2016 - 2025)

Gyre Therapeutics (GYRE) has disclosed Other Non Operating Income for 11 consecutive years, with $727000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Non Operating Income rose 221.57% to $727000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was -$72000.0, a 97.49% increase, with the full-year FY2024 number at -$1.7 million, changed N/A from a year prior.
  • Other Non Operating Income was $727000.0 for Q3 2025 at Gyre Therapeutics, up from -$145000.0 in the prior quarter.
  • In the past five years, Other Non Operating Income ranged from a high of $858000.0 in Q4 2022 to a low of -$2.0 million in Q3 2023.
  • A 5-year average of -$81333.3 and a median of -$14000.0 in 2021 define the central range for Other Non Operating Income.
  • Peak YoY movement for Other Non Operating Income: skyrocketed 7250.0% in 2022, then tumbled 197500.0% in 2023.
  • Gyre Therapeutics' Other Non Operating Income stood at -$12000.0 in 2021, then surged by 7250.0% to $858000.0 in 2022, then crashed by 330.3% to -$2.0 million in 2023, then soared by 61.49% to -$761000.0 in 2024, then surged by 195.53% to $727000.0 in 2025.
  • Per Business Quant, the three most recent readings for GYRE's Other Non Operating Income are $727000.0 (Q3 2025), -$145000.0 (Q2 2025), and $107000.0 (Q1 2025).